基于18F-FDG PET/CT的模型开发与验证:预测晚期卵巢癌初次肿瘤细胞减灭术中实现完全细胞减灭
该回顾性研究纳入2家三级中心2013年6月至2020年2月间接受初次肿瘤细胞减灭术的III-IV期卵巢癌患者,利用PET/CT参数构建预测完全细胞减灭的模型。最佳多变量模型包含CA-125(<750或≥750 IU/mL)、转移灶数目(<2或≥2)及A区代谢肿瘤体积,训练集AUC为0.768,测试集验证AUC为0.771。
要点
- 训练集159例、测试集166例,测试集中65.4%实现完全细胞减灭,中位年龄55岁。
- 最佳模型纳入CA-125、转移灶数目及肾静脉上缘以上区域代谢肿瘤体积,训练集AUC 0.768。
- 模型在测试集外部验证AUC为0.771,可用于临床筛选初次肿瘤细胞减灭术患者。
核心结论
- 研究成功开发并验证了一个术前模型,用于预测晚期卵巢癌患者初次肿瘤细胞减灭术中实现完全细胞减灭。
- 该模型可在临床实践中辅助筛选适合初次肿瘤细胞减灭术的患者。
研究设计与样本
- 回顾性研究,纳入2家三级中心2013年6月至2020年2月间接受初次肿瘤细胞减灭术的III-IV期卵巢癌患者。
- 各医院患者分别分配至训练集和测试集,训练集159例,测试集166例。
- 将腹腔分为3个区域,通过图像分析收集PET/CT衍生参数,并结合临床病理特征构建多种预测模型。
- 选择受试者工作特征曲线下面积(AUC)最高的模型进行外部验证。
主要发现
- 测试集中位年龄55岁,72.3%为III期肿瘤,65.4%实现完全细胞减灭。
- PET/CT参数中筛选出代谢肿瘤体积、总病灶糖酵解及肾静脉上缘以上区域(A区)转移灶数目。
- 最佳预测多变量模型由CA-125(<750或≥750 IU/mL)、转移灶数目(<2或≥2)及A区代谢肿瘤体积组成,训练集预测完全细胞减灭的AUC为0.768。
- 该模型在测试集验证的AUC为0.771。
关键数值与推荐
- 最佳模型预测完全细胞减灭的训练集AUC为0.768,测试集验证AUC为0.771。
- 模型纳入变量:CA-125(<750或≥750 IU/mL)、转移灶数目(<2或≥2)、A区代谢肿瘤体积。
临床怎么用
- 作者认为该术前模型可促进临床实践中初次肿瘤细胞减灭术的患者选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to develop an 18F-FDG PET/CT-based model to predict complete cytoreduction during primary cytoreductive surgery (CRS) for ovarian cancer (OC). PATIENTS AND METHODS: We retrospectively identified patients with stage III-IV OC who underwent primary CRS between June 2013 and February 2020 at 2 tertiary centers. Patients from each hospital were assigned to training and test sets. The abdominal cavity was divided into 3 sections, and data for the PET/CT-derived parameters were collected through image analysis. Various prediction models were constructed by combining clinicopathologic characteristics and PET/CT-derived parameters. The performance of the model with the highest area under the receiver operating characteristic curve (AUC) was externally validated. RESULTS: The training and test sets included 159 and 166 patients, respectively. The median age of patients in the test set was 55 years; 72.3% of them had stage III tumors, and 65.4% underwent complete cytoreduction. Metabolic tumor volume, total lesion glycolysis, and the number of metastatic lesions above the upper margin of the renal vein (area A) were selected among the PET/CT parameters. The best predictive multivariable model consisted of CA-125 (<750 or ≥750 IU/mL), number of metastatic lesions (<2 or ≥2), and metabolic tumor volume of area A, predicting complete cytoreduction with an AUC of 0.768. The model was validated using a test set. Its predictive performance yielded an AUC of 0.771. CONCLUSIONS: We successfully developed and validated a preoperative model to predict complete cytoreduction in advanced OC. This model can facilitate patient selection for primary CRS in clinical practice.
引用
- Kim J, Gil J, Kim SI, et al. Development and Validation of 18F-FDG PET/CT-Based Models for Predicting Successful Complete Cytoreduction During Primary Cytoreductive Surgery for Advanced Ovarian cancer. Clin Nucl Med. 2022. PMID: 36607373. doi:10.1097/RLU.0000000000004417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。